Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berubitinib + PLB1004 in EGFR-mutant, MET-amplified NSCLC after EGFR-TKI failure
CTR20231603Phase 2Active
- Sponsor
- Anshi Pharma
- Start
- Jun 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vebreltinib, andamertinib in non-small cell lung cancer (NSCLC), sponsored by Anshi Pharma. Started Jun 2023; status: active.
02
Drugs
vebreltinibandamertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231603.